GNW-Adhoc: Merus takes part in fireside chat at this year’s Jefferies Healthcare Conference

^UTRECHT, Netherlands and CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) —

Merus NV ( (Nasdaq: MRUS), a sector company

clinical oncology, the innovative multispecific antibody in full

length (Biclonics(®) and Triclonics(®) ), announced today that

that Bill Lundberg, MD, President and Chief Executive Officer of Merus, am

Wednesday, June 7, 2023 at 11:30 a.m. Eastern Time as part of the

participate in a fireside chat at this year’s Jefferies Healthcare Conference


The presentation will be webcast simultaneously on the company’s website at the

Investors section ( are available.

A recording of the presentation will also be available there for a limited time

period to be available.

About Merus

Merus ( is a clinical oncology company

Company that innovative bispecific and trispecific

Developed full-length antibody therapeutics known as Multiclonics



Multiclonics(®) are manufactured using industry standard processes

manufactured. It has been observed in preclinical and clinical studies that

several characteristics of Multiclonics with the characteristics of conventional human

monoclonal antibodies are identical, e.g. B. long half-life and low

immunogenicity. Visit the Merus website for more information

( and on Twitter (

Multiclonics(®), Biclonics(®) and Triclonics(®) are registered trademarks of

Merus NV


Selected leveraged products on Merus BVWith knock-outs, speculative investors can participate disproportionately in price movements. Simply select the desired leverage and we will show you suitable open-end products on Merus BV

Leverage must be between 2 and 20

No data